Gujarat Themis Biosyn informs about outcome of board meeting

04 Nov 2023 Evaluate

Pursuant to Regulation 30 of the Listing Regulations, Gujarat Themis Biosyn has informed that the Board of Directors of the Company, at its meeting held today on Saturday, 4th November, 2023, has approved the following: The Unaudited Standalone Financial Results for the Quarter and Half year ended 30th September, 2023. A copy of Unaudited Standalone Financial Results for the Quarter and Half year ended 30th September, 2023 together with Limited Review Report is enclosed and the proposal to enter into Master Service Agreement with its Related Party, Themis Medicare. The details required as per SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 read with Regulation 30A of the Listing Regulations are enclosed as Annexure - I. The meeting commenced at 10:00 and concluded at 11:15 am.

The above information is a part of company’s filings submitted to BSE.







Guj. Themis Biosyn Share Price

414.15 11.85 (2.95%)
14-May-2024 15:44 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1545.25
Dr. Reddys Lab 5861.00
Cipla 1356.95
Zydus Lifesciences 987.05
Lupin 1635.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.